CSB 2.009 Note
4r. Dihydroetorphine.
CSB 2.009 History
History:
CR 01-071: Cr.
Register November 2001 No. 551, eff. 12-1-01.
CSB 2.009 Note
CSB 2.28 Addition of dichloralphenazone to schedule IV. (1) Section
961.20 (2) (cs), Stats., is created to read:
CSB 2.009 History
History:
CR 02-025: Cr.
Register October 2002 No. 562, eff. 11-1-02.
CSB 2.009 Note
CSB 2.29 Transfer of buprenorphine from schedule V to schedule III. (1) Section
961.18 (5m), Stats., is created to read:
CSB 2.009 NoteSection 961.18 (5m) Narcotic Drugs Not Limited by Quantity. Any material, compound, mixture, or preparation containing any of the following narcotic drugs, including any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation:
CSB 2.009 Note
(a) Buprenorphine
CSB 2.009 History
History:
CR 03-056: cr.
Register January 2004 No. 577, eff. 2-1-04.
CSB 2.009 Note
CSB 2.30 Addition of gamma-hydroxybutyric acid to schedule III. (1) Section
961.18 (3) (o), Stats., is created to read:
CSB 2.009 NoteSection 961.18 (3) (o) Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal food, drug and cosmetic act:
CSB 2.009 Note
1. Gamma-hydroxybutyric acid.
CSB 2.009 History
History:
CR 03-057: cr.
Register January 2004 No. 577, eff. 2-1-04.
CSB 2.009 Note
CSB 2.31 Addition of 2,5 dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7) to schedule I. (1) Section
961.14 (4) (wh), Stats., is created to read:
CSB 2.009 NoteSection 961.14 (4) (wh) 2,5 dimethoxy-4-(n)- propylthiophenethylamine, commonly known as “2C-T-7";
CSB 2.009 History
History:
CR 06-058: cr.
Register April 2007 No. 616, eff. 5-1-07.
CSB 2.009 Note
CSB 2.32 Addition of N- benzylpiperazine (BZP) to schedule I. (1) Section
961.14 (7) (q), Stats., is created to read:
CSB 2.009 NoteSection 961.14 (7) (q) N- benzylpiperazine, commonly known as “BZP."
CSB 2.009 History
History:
CR 06-058: cr.
Register April 2007 No. 616, eff. 5-1-07.
CSB 2.009 Note
CSB 2.33 Addition of alpha-methyltryptamine (AMT) to schedule I. (1) Section
961.14 (4) (wi), Stats., is created to read:
CSB 2.009 NoteSection 961.14 (4) (wi) Alpha-methyltryptamine, commonly known as “AMT";
CSB 2.009 History
History:
CR 06-059: cr.
Register April 2007 No. 616, eff. 5-1-07.
CSB 2.009 Note
CSB 2.34 Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT). (1) Section
961.14 (4) (wj), Stats., is created to read:
CSB 2.009 NoteSection 961.14 (4) (wj) 5-methoxy-N, N-diisopropyltryptamine, commonly known as “5-MeO-DIPT";
CSB 2.009 History
History:
CR 06-059: cr.
Register April 2007 No. 616, eff. 5-1-07.
CSB 2.009 Note
CSB 2.35 Addition of lisdexamfetamine to schedule II. (1) Section
961.16 (5) (e), Stats., is created to read:
CSB 2.009 NoteSection 961.16 (5) (e) Lisdexamfetamine, commonly known as “Vyvanse TM."
CSB 2.009 History
History:
CR 10-112: cr.
Register April 2011 No. 664, eff. 5-1-11.
CSB 2.009 Note
CSB 2.36 Addition of tramadol to schedule IV. Section
961.20 (4) (e), Stats., is created to read:
CSB 2.009 NoteSection 961.20 (4) (e) Tramadol, including any of its isomers and salts of isomers. CSB 2.009 History
History:
cr. Affirmative action order under s.
968.11 (4), Stats.,
Register August 2014 No. 704, eff. 9-1-14;
CR 15-008: cr.
Register October 2015 No. 718, eff. 11-1-15.
CSB 2.009 Note
CSB 2.37 Rescheduling of hydrocodone combination products. Sections 961.18 (5) (c) and (d), Stats., are repealed.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2014 No. 706, eff. 11-1-14;
CR 15-007: cr.
Register October 2015 No. 718, eff. 11-1-15.
CSB 2.009 Note
CSB 2.38 Addition of suvorexant to schedule IV. Section
961.20 (2) (mr), Stats., is created to read:
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2014 No. 706, eff. 11-1-14;
CR 15-009: cr.
Register October 2015 No. 718, eff. 11-1-15.
CSB 2.009 Note
961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, nalmefene,
naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register April 2015 No. 711B, eff. 4-1-15;
CR 15-068: cr.
Register August 2016 No. 728, eff. 9-1-16.
CSB 2.009 Note
CSB 2.40 Exclusion of [123
I]ioflupane. Section
961.16 (2) (b), Stats., is amended to read:
CSB 2.009 Note
(b) Coca leaves and any salt, compound, derivative or preparation of coca leaves. Decocainized coca leaves or extractions which do not contain cocaine or ecgonine are excluded from this paragraph. [123I]Ioflupane is excluded from this paragraph. The following substances and any of their salts, esters, isomers and salts of esters and isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2015 No. 718A3, eff. 10-19-15; correction made under s.
35.17, Stats.,
Register October 2015 No. 718;
CR 16-060: cr.
Register May 2017 No. 737, eff. 6-1-17.
CSB 2.009 Note
CSB 2.41 Scheduling of beta-hydroxythiofentanyl and butyryl fentanyl. Sections
961.14 (2) (eu) and
(ey) are created to read:
CSB 2.009 Note
961.14 (2) (eu) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)
CSB 2.009 Note
(ey) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide)
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2016 No. 728, eff. 7-18-16;
CR 16-081: cr.
Register July 2017 No. 739, eff. 8-1-17.
CSB 2.009 Note
CSB 2.42 Scheduling of furanyl fentanyl. Section
961.14 (2) (ne) is created to read:
CSB 2.009 Note
961.14 (2) (ne) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide).
CSB 2.009 History
History:
EmR1626: emerg. cr., eff. 9-1-16;
CR 16-059: cr.
Register May 2017 No. 737, eff. 6-1-17.
CSB 2.009 Note
CSB 2.43 Addition of brivaracetam to schedule V. Section
961.22 (6), Stats., is created to read:
CSB 2.009 Note
961.22 (6) BRIVARACETAM. Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide), including its salts, isomers or salts of isomers.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register September 2016 No. 729, eff. 9-26-16;
CR 17-009: cr.
Register July 2017 No. 739, eff. 8-1-17.
CSB 2.009 Note
CSB 2.44 Addition of thiafentanil to schedule II. Section
961.16 (3) (zx), Stats., is created to read:
CSB 2.009 Note
961.16 (3) (zx) Thiafentanil.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2016 No. 730, eff. 10-3-16;
CR 17-007: cr.
Register July 2017 No. 739, eff. 8-1-17.
CSB 2.009 Note
CSB 2.45 Addition of AB-FUBINACA and ADB-PINACA to schedule I. Section
961.14 (4) (tb) 32. and
33., Stats., is created to read:
CSB 2.009 Note
961.14 (4) (tb) 32. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as AB-FUBINACA.
33. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, commonly known as ADB-PINACA.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2016 No. 730, eff. 10-10-16;
CR 17-008: cr.
Register July 2017 No. 739, eff. 8-1-17.
CSB 2.009 Note
CSB 2.46 Addition of acetyl fentanyl to schedule I. Section
961.14 (2) (ae), Stats., is created to read:
CSB 2.009 Note
961.14 (2) (ae) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide).
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2016 No. 731, eff. 11-21-16;
CR 17-021: cr.
Register November 2017 No. 743, eff. 12-1-17.
CSB 2.009 Note
CSB 2.47 Addition of AH-7921 to schedule I. Section
961.14 (2) (aj), Stats., is created to read:
CSB 2.009 Note
961.14 (2) (aj) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide).
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2016 No. 731, eff. 11-21-16;
CR 17-023: cr.
Register November 2017 No. 743, eff. 12-1-17.
CSB 2.009 Note
CSB 2.48 Addition of eluxadoline to schedule IV. Section
961.20 (4) (cm), Stats., is created to read:
CSB 2.009 Note
961.20 (4) (cm) Eluxadoline, including any of its isomers, and salts of isomers.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2016 No. 731, eff. 11-21-16;
CR 17-022: cr.
Register November 2017 No. 743, eff. 12-1-17.
CSB 2.009 Note
CSB 2.49 Addition of U-47700 to schedule I. Section
961.14 (2) (z), Stats., is created to read:
CSB 2.009 Note
961.14 (2) (z) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide).
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register December 2016 No. 732, eff. 12-19-16;
CR 17-020: cr.
Register November 2017 No. 743, eff. 12-1-17.
CSB 2.009 Note
CSB 2.50 Addition of AB-CHMINACA, AB-PINACA and THJ-2201 to schedule I. Section
961.14 (4) (tb) 34.,
35., and
36., Stats., are created to read:
CSB 2.009 Note
961.14 (4) (tb) 34. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as AB-CHMINACA.
CSB 2.009 Note
35. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, commonly known as AB-PINACA).
CSB 2.009 Note
36. [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone, commonly known as THJ-2201.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register April 2017 No. 736, eff. 3-27-17; correction in (intro.) made under s.
35.17, Stats.,
Register April 2017 No. 736;
CR 17-085: cr.
Register October 2018 No. 754, eff. 11-1-18; correction in (intro.) made under s.
35.17, Stats.,
Register October 2018 No. 754.
CSB 2.009 Note
CSB 2.51 Addition of MAB-CHMINACA to schedule I. Section
961.14 (4) (tb) 37., Stats., is created to read:
CSB 2.009 Note
961.14 (4) (tb) 37. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as MAB-CHMINACA or ADB-CHMINACA.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register April 2017 No. 736, eff. 3-27-17;
CR 17-086: cr.
Register October 2018 No. 754, eff. 11-1-18.
CSB 2.009 Note
CSB 2.52 Addition of 4-MePPP and a-PBP to schedule I. Section
961.14 (7) (L) 32. and
33., Stats., is created to read:
CSB 2.009 Note
961.14 (7) (L) 32. 4-methyl-alpha-pyrrolidinopropiophenone, commonly known as 4-MePPP.
CSB 2.009 Note
33. Alpha-pyrrolidinobutiophenone, commonly known as a-PBP.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register April 2017 No. 736, eff. 4-10-17;
CR 17-087: cr.
Register October 2018 No. 754, eff. 11-1-18.
CSB 2.009 Note
CSB 2.53 Scheduling of acryl fentanyl. Section
961.14 (2) (ai), Stats., is created to read:
CSB 2.009 Note
961.14 (2) (ai) Acryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-2-propenamide);
CSB 2.009 Note Section 961.14 (2) (ai), Stats., was renumbered to s. 961.14 (2) (nd) 3. by
2017 Wis. Act 60.
CSB 2.009 History
History:
EmR1710: emerg. cr., eff. 5-2-17;
CR 17-040: cr.
Register November 2017 No. 743, eff. 12-1-17; correction made under s.
35.17, Stats.,
Register November 2017 No. 743.
CSB 2.009 Note
CSB 2.54 Addition of oral solutions containing dronabinol to schedule II. Section
961.16 (10), Stats., is created to read:
CSB 2.009 Note
961.16 (10) (a) Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral solution in a drug product approved by the U.S. food and drug administration.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register May 2017 No. 737, eff. 5-15-17;
CR 18-055: cr.
Register June 2019 No. 762, eff. 7-1-19.
